Astrocytes Pharmaceuticals >>
astrocytepharma.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
1-10
employees, estimated range
Grants
$4.8M
3 grants · CORDIS
Backers
1
Boston Harbor Angels
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 12, 2025
Won a grant $1.5M · CORDIS
Sep 30, 2018
Won a grant $298k · CORDIS
Sep 30, 2018
Won a grant $3M · CORDIS
Funding rounds
Backed byfrom the funds' portfolios and accelerator catalogs
Boston Harbor Angels Investors in similar startupsfunds that back the companies most like this one
backs CranioSense
backs AtalantaTx
Similar startupsby what they do, their industry and backers
We can do better.. Following a traumatic brain injury (TBI), elevated cranial pressure can lead to serious health issues: brain damage…
Draupnir Bio is developing new innovative therapies for patients.
Damona Pharmaceuticals is developing precision neuromedicines to reverse cognitive deficits associated with brain disorders.associated with…
Developing intravenous recombinant human decorin to treat dystrophic epidermis bullosa.. Kamal Therapeutics, Inc.
Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
At BRAINBox Solutions, our multi-modality approach aims to aid clinicians with the diagnosis of traumatic brain injury and what comes next.
News
Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-004
Enrollment Complete in STARFAST Sports-Related Concussion Trial;Topline Results Expected This Winter GROTON, CT (September 30, 2026) - Astrocyte Pharmaceuticals Inc., a pioneering clinical-stage biotechnology company developing first-in-class cerebroprote
Read more
Report
Astrocyte Pharmaceuticals Receives NIH Award to Evaluate AST-004 in Substance Use Disorders
$400,000 program extends AST-004 into another major CNS indication and reinforces the breadth of its cerebroprotective potential Groton, CT - August 25, 2026 - Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company developing first-in-clas
Read more
Report
Astrocyte delivering first-in-class approach to brain injury neuroprotection
Closely held Astrocyte Pharmaceuticals is developing a new category of neuroprotective therapies aimed at reducing early brain damage following stroke, concussion, and traumatic brain injury (TBI). By harnessing the natural caretaker functions of astrocyt
Read more
Report
Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH Grant
Groton, CT, June 17, 2025 - Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company today announced two major milestones that could change the way we protect brains from the damage caused by concussions and repeat head impacts - one of the
Read more
Report
Game-Changing Neuroprotection: Astrocyte Pharmaceuticals Breakthrough in Brain Injury Treatment
For too long, the best available treatments for concussions and brain injuries have been limited to rest and observation. Astrocyte Pharma, however, is disrupting the playing field with its
Read more
Report
Groton company to test new treatment to protect brain after injury
Groton - A local company is about to begin testing a drug therapy designed to protect the brain after it is injured.
Read more
Report
Senator Chris Murphy Highlights Groton's Astrocyte Pharmaceuticals As "Innovator Of The Month"
August 19, 2024 U.S. Senator Chris Murphy (D-Conn.) HARTFORD-U.S. Senator Chris Murphy (D-Conn.) on Monday announced that Astrocyte Pharmaceuticals, a Groton-based clinical-stage biopharmaceuticals company, was named "Innovator of the Month" for their wor
Read more
Report
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
Green Light for Phase 2 Trial of AST-004 in Acute Ischemic Stroke Patients Groton, CT, March 12, 2024 - Astrocyte Pharmaceuticals Inc., a clinical-stage biopharmaceutical company committed to advancing cerebroprotective therapies for individuals suffering
Read more
Report
Alzheimer's Drug Discovery Foundation Joins Astrocyte Pharmaceuticals' $6M+ Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004
Groton, CT, August 18, 2023 - Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financin
Read more
Report
Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke
Groton, CT, April 10, 2023 - Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today announced that Theodore Liston, Ph.D., Vice President of R
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cambridge
United States
HQ
Groton
United States
Regional office
Contact
93 Shennecossett Road, Groton, CT 06340, 245 First Street; Suite 1800, Cambridge, MA 02142